Drug interactions involving warfarin: Practice tool and practical management tips

Canadian Pharmacists Journal

Volumn 144, Issue 1, 2011, Pages

  Bungard, Tammy J ^a   Yakiwchuk, Erin ^b   Foisy, Michelle ^c   Brocklebank, Cynthia ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AMPRENAVIR; ATAZANAVIR; AZATHIOPRINE; AZITHROMYCIN; BISMUTH SALICYLATE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BOSENTAN; CARBAMAZEPINE; CELECOXIB; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CLOPIDOGREL; COLESTYRAMINE; DICLOFENAC; IBUPROFEN; INDOMETACIN; MERCAPTOPURINE; NAPROXEN; PARACETAMOL; PROTHROMBIN; SALICYLIC ACID METHYL ESTER; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 79951733707     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.3821/1913-701X-144.1.21     Document Type: Article

References (66)

1. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):160S-198S.
2. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084-97.
3. International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64. Erratum in: N Engl J Med 2009;361:1613 (dosage error in article text).
4. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and foods. Ann Intern Med 1994;121:676-83.
5. Bungard TJ, Roberston P, Schindel T. Course 9018: Anticoagulation: on the road to practice change. Edmonton (AB): University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences, Office of Continuing Pharmacy Education; 2008. Available: www.pharmacy.ualberta.ca/PD/courses/anticoag/anticoag.html (accessed Nov. 24, 2009).
6. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21.
7. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances and foods. J Clin Pharmacol 2005;45:127-32.
8. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508-9.
9. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
10. Micromedex [database]. Thomson Reuters Healthcare. Available: www.thomsonhc.com/hcs/librarian (accessed Nov. 24, 2009).
11. Shek KAL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. Pharmacotherapy 1999;19:1153-8.
12. Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin and the thyroid gland. Medicine (Baltimore) 2004;83:107-13.
13. Telzir (fosamprenavir) [package insert]. Mississauga (ON): GlaxoSmithKline Inc.; October 2009.
14. Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf 2010;9:215-23.
15. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:513-38.
16. Reyataz (atazanavir) [package insert]. Montreal (QC): Bristol-Myers Squibb Canada; April 2008.
17. Toronto General Hospital. Drug interaction tables. Immunodeficiency Clinic; 2010. Available: www.hivclinic.ca/main/drugs_interact.html (accessed Nov. 25, 2009).
18. Vazquez SR, Rondina MT, Pendleton RC. Azathioprine-induced warfarin resistance. Ann Pharmacother 2008;42:1118-23.
19. Shrader SP, Fermo JD, Dzikowski AL. Azithromycin and warfarin interaction. Pharmacotherapy 2004;24:945-79.
20. Parrish RH, Pazdur DE, O'Donnell PJ. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature. Pharmacotherapy 2006;26:1650-3.
21. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
22. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000;63:28-31.
23. Dandekar SS, Laidlaw DAH. Suprachoroidal haemorrhage after addition of clarithromycin to warfarin. J R Soc Med 2001;94:583-4.
24. Meeks ML, Mahaffey KW, Katz KW. Danazol increases the anticoagulant effect of warfarin. Ann Pharmacother 1992;26:641-2.
25. Prezista (darunavir) [package insert]. Toronto (ON): Janssen-Ortho Inc.; March 2009.
26. Sekar V, Spinosa-Guzman S, Meyvisch P, et al. Cocktail study to investigate the in-vivo drug interaction potential of darunavir co-administered with low-dose ritonavir (DRV/r) on cytochrome P450 enzymes 2D6, 2C9 and 2C19 [abstract P23]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; Apr. 7-9, 2008; New Orleans (LA).
27. Rescriptor (delavirdine) [package insert]. Kirkland (QC): Pfizer Canada Inc.; September 2003.
28. Hasan SA. Interaction of doxycycline and warfarin: an enhanced anticoagulant effect. Cornea 2007;26:742-3.
29. Multaq (dronedarone tablets) [package insert]. Laval (QC): Sanofi-aventis Canada Inc.; July 31, 2009.
30. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-7.
31. Intelence (etravirine) [package insert]. Toronto (ON): Ortho-Biotech, Janssen-Ortho Inc.; March 2008.
32. Breault R, Klacowicz A, George-Phillips KL, Bungard TJ. Warfarin dosing after initiation of fenofibrate. Can J Hosp Pharm 2005;58:31-3.
33. Allison EJ, McKinney TJ, Langenberg JN. Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur J Emerg Med 2002;9:175-7.
34. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004;24:285-90.
35. Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009;29:744-8.
36. Lexi-Comp Online. Lexi-Interact. Hudson (OH): Lexi-Comp, Inc.; 2010. Available: http://online.lexi.com/crlsql/servlet/crlonline (accessed Mar. 19, 2010).
37. Gatti G, Alessandrini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998;12:825-6.
38. Fiallo P. Reduced therapeutic activity of warfarin during treatment with oral isotretinoin. Br J Dermatol 2004;150:164-6.
39. Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006;26:868-71.
40. Levofloxacin and warfarin interaction. Pharmacotherapy 2001;21:884-5.
41. Carroll DN, Carroll DG. Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 2008;42:680-5.
42. Hughes CA, Freitas AJ, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007;177:357-9.
43. Fulco PP, Zingone MM, Higgison RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 2008;28:945-9.
44. Marinella MA. Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother 1998;32:841-2.
45. Joss JD, LeBlond RF. Potentiation of warfarin anticoagulation associated with topical methyl salicylate. Ann Pharmacother 2000;34:729-33.
46. Thirion DJG, Farquhar LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 2000;20:98-9.
47. Silingardi M, Ghirarduzzi A, Tincani E, et al. Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 2000;83:794-5.
48. Arnold AM, Nissen LR, Hg TMH. Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy 2005;25:904-7.
49. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999;13:1788-9.
50. Lietdke MD, Rathburn RC. Warfarin-antiretroviral interactions. Ann Pharmacother 2009;43:322-8.
51. Dionisioa D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001;15:277-8.
52. Hassan Y, Awaisu A, Aziz NA, Ismail O. The complexity of achieving anticoagulation control in the face of warfarin-phenytoin interaction: an Asian case report. Pharm World Sci 2005;27:16-9.
53. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987;42:305-11.
54. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol 1999;94:382-3.
55. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother 2002;36:72-4.
56. Lee CR, Thrasher KA. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 2001;21:1240-6.
57. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-302.
58. Llibre JM, Romeu J, Lopez E, Sirera G. Severe interaction between ritonavir and acenocoumarol. Ann Pharmacother 2002;36:621-3.
59. Barry M. Rosuvastatin-warfarin drug interaction. Lancet 2004;363:328.
60. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir. Ann Pharmacother 1997;31:647.
61. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother 2007;41:1292-5.
62. Cook DE, Ponte CD. Suspected trimethoprim/sulfamethoxazole-induced hypoprothrombinemia. J Fam Pract 1994;39:589-91.
63. Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis 2008;26:44-8.
64. Teefy AM, Martin JE, Kovacs MJ. Warfarin resistance due to sulfasalazine. Ann Pharmacother 2000;34:1265-8.
65. Aptivus (tipranavir) [package insert]. Ridgefield (CT): Boehringer Ingleheim Pharmaceuticals, Inc.; June 2009.
66. Dumo PA, Kielbasa LA. Successful anticoagulation and continuation of tramadol therapy in the setting of a tramadol-warfarin interaction. Pharmacotherapy 2006;26:1654-7.